Last reviewed · How we verify

NCT05961046

Visual Performance of the Vivity IOL in Post-myopic LASIK and PRK Patients

Terminated Last updated 17 June 2024
What this trial tests

trial testing Vivity IOL in Cataract in 6 participants. Terminated before completion.

Timeline
17 August 2023
Primary endpoint
13 June 2024
13 June 2024

Quick facts

Lead sponsorLaser & Corneal Surgery Associates
StatusTerminated
Study typeOBSERVATIONAL
Enrollment6
Start date17 August 2023
Primary completion13 June 2024
Estimated completion13 June 2024
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Laser & Corneal Surgery Associates

Who can join

40 and older, any sex, with Cataract. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective is to evaluate visual outcomes and patient satisfaction in patients with a history of myopic LASIK or PRK who will have completed cataract surgery with the Vivity IOL.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Vivity IOL

Trials testing the same drug.

Other recruiting trials for Cataract

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05961046.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing